ES2084821T3 - Composicion para estabilizar el plasma sanguineo en curso de pasteurizado. - Google Patents

Composicion para estabilizar el plasma sanguineo en curso de pasteurizado.

Info

Publication number
ES2084821T3
ES2084821T3 ES91912152T ES91912152T ES2084821T3 ES 2084821 T3 ES2084821 T3 ES 2084821T3 ES 91912152 T ES91912152 T ES 91912152T ES 91912152 T ES91912152 T ES 91912152T ES 2084821 T3 ES2084821 T3 ES 2084821T3
Authority
ES
Spain
Prior art keywords
composition
blood plasma
pasteurizing
course
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91912152T
Other languages
English (en)
Inventor
Myriana Burnouf
Thierry Burnouf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Regional de Transfusion Sanguine de Lille
Centre Regional de Transfusion Sanguine
Original Assignee
Centre Regional de Transfusion Sanguine de Lille
Centre Regional de Transfusion Sanguine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Regional de Transfusion Sanguine de Lille, Centre Regional de Transfusion Sanguine filed Critical Centre Regional de Transfusion Sanguine de Lille
Application granted granted Critical
Publication of ES2084821T3 publication Critical patent/ES2084821T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6443—Coagulation factor XIa (3.4.21.27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21027—Coagulation factor XIa (3.4.21.27)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION DESTINADA A ESTABILIZAR EL PLASMA SANGUINEO, TOTAL O DEPROVISTO DE CRIOPROTEINAS, DURANTE LA PASTEURIZACION. LA COMPOSICION SEGUN LA INVENCION PERMITE PASTEURIZAR VOLUMENES DE PLASMA MUY GRANDES (HASTA VARIOS CENTENARES DE LITROS). LA INVENCION TAMBIEN SE REFIERE AL PROCESO DE PASTEURIZACION DEL PLASMA QUE UTILIZA LA COMPOSICION ESTABILIZANTE. EL PLASMA PASTEURIZADO OBTENIDO SE DESTINA A UN USO TERAPEUTICO.
ES91912152T 1990-07-03 1991-06-20 Composicion para estabilizar el plasma sanguineo en curso de pasteurizado. Expired - Lifetime ES2084821T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9008375A FR2664165B1 (fr) 1990-07-03 1990-07-03 Composition pour stabiliser le plasma sanguin en cours de pasteurisation.

Publications (1)

Publication Number Publication Date
ES2084821T3 true ES2084821T3 (es) 1996-05-16

Family

ID=9398269

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91912152T Expired - Lifetime ES2084821T3 (es) 1990-07-03 1991-06-20 Composicion para estabilizar el plasma sanguineo en curso de pasteurizado.

Country Status (22)

Country Link
EP (1) EP0497929B1 (es)
JP (1) JP3132828B2 (es)
AT (1) ATE135238T1 (es)
AU (1) AU8062991A (es)
CA (1) CA2065284A1 (es)
CZ (1) CZ281431B6 (es)
DE (1) DE69117920T2 (es)
DK (1) DK0497929T3 (es)
ES (1) ES2084821T3 (es)
FI (1) FI96918C (es)
FR (1) FR2664165B1 (es)
GR (1) GR3020048T3 (es)
HU (1) HU208404B (es)
LT (1) LT3419B (es)
LV (1) LV10384B (es)
NO (1) NO179127C (es)
PL (1) PL166579B1 (es)
PT (1) PT98190B (es)
RU (1) RU2045902C1 (es)
SK (1) SK279031B6 (es)
WO (1) WO1992000767A1 (es)
ZA (1) ZA914848B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687317B1 (fr) 1992-02-13 1995-06-23 Aetsrn Composition pour stabiliser le plasma sanguin en cour de pasteurisation et solution plasmatique pasteurisee a usage therapeutique.
DE4240103A1 (de) * 1992-05-26 1993-12-02 Behringwerke Ag Verfahren zur Inaktivierung von Viren in Präparationen von Proteinen
DE19508192A1 (de) * 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
US20060019234A1 (en) * 2004-07-22 2006-01-26 Shanbrom Technologies, Llc Modern blood banking employing improved cell preservation composition
US11682319B2 (en) 2016-03-10 2023-06-20 Intuitive Surgical Operations, Inc. Fake blood for use in simulated surgical procedures

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
EP0035204B2 (en) 1980-03-05 1991-05-22 Miles Inc. Pasteurized therapeutically active protein compositions
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
DE3336631A1 (de) * 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
DK18288D0 (da) * 1988-01-15 1988-01-15 Nordisk Gentofte Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii

Also Published As

Publication number Publication date
EP0497929A1 (fr) 1992-08-12
NO920791L (no) 1992-02-28
FR2664165A1 (fr) 1992-01-10
PL294037A1 (en) 1993-01-11
LV10384A (lv) 1995-02-20
DK0497929T3 (da) 1996-07-22
CZ281431B6 (cs) 1996-09-11
RU2045902C1 (ru) 1995-10-20
FI96918C (fi) 1996-09-25
GR3020048T3 (en) 1996-08-31
CA2065284A1 (fr) 1992-01-04
WO1992000767A1 (fr) 1992-01-23
FI920934A0 (fi) 1992-03-02
FI96918B (fi) 1996-06-14
SK279031B6 (sk) 1998-05-06
AU8062991A (en) 1992-02-04
NO920791D0 (no) 1992-02-28
HU9200701D0 (en) 1992-05-28
EP0497929B1 (fr) 1996-03-13
JPH05501417A (ja) 1993-03-18
DE69117920T2 (de) 1996-10-02
PL166579B1 (pl) 1995-06-30
DE69117920D1 (de) 1996-04-18
FR2664165B1 (fr) 1992-10-16
HU208404B (en) 1993-10-28
CS57992A3 (en) 1992-08-12
ZA914848B (en) 1992-04-29
LTIP264A (en) 1994-10-25
PT98190A (pt) 1992-05-29
LT3419B (en) 1995-09-25
HUT60148A (en) 1992-08-28
NO179127B (no) 1996-05-06
ATE135238T1 (de) 1996-03-15
NO179127C (no) 1996-08-14
LV10384B (en) 1995-04-20
PT98190B (pt) 1998-12-31
JP3132828B2 (ja) 2001-02-05

Similar Documents

Publication Publication Date Title
ES2121065T3 (es) Composicion para estabilizar el plasma sanguineo durante el pasteurizado y procedimiento de pasteurizado que comprende la utilizacion de esta composicion.
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
ES8802273A1 (es) Procedimiento para la inactivacion de germenes patogenos filtrables,capaces de reproducirse,en productos sanguineos
SE8406538D0 (sv) Novel derivatives of purine
SE8402551D0 (sv) Cinnamoylmoranolin-derivat
MX9204454A (es) Derivados de tiourea para inhibir la replicacion del virus de inmunodeficiencia humana y formulado farmaceutico que los contiene.
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
SE8703854D0 (sv) Prostaglandinderivat for behandling av glaukom eller okuler hypertension
FI873905A0 (fi) Terapeutisk komposition och foerfarande.
ES2084821T3 (es) Composicion para estabilizar el plasma sanguineo en curso de pasteurizado.
DK0463126T3 (da) Fremgangsmåder til fremme af sårheling og genopretning af væv
ES2091183T3 (es) Metodo para mejorar el sueño.
NO924453D0 (no) Fremgangsmaate for fremstilling av et pasteurisert trombinkonsentrat
ES2066753T3 (es) Uso de un preparado, que contiene inmunoglobulina, para la profilaxis y la terapia del sida, en personas.
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
ES2166838T3 (es) 6-(triazolil(3-(trifluorometil)fenil)metil)-2-quinolinonas y -quinolinationas.
DK374887A (da) 2-acyloxypropropylamin-derivater, deres fremstilling og anvendelse
DK30581A (da) Fremgangsmaade til fremstilling af 5-aminotetrazolderivater af retinsyrer
ITAP930004U1 (it) Sistema di correzione del procurvato e del recurvato per allungatori di arti

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 497929

Country of ref document: ES